BridgeBio CAO sells 2,000 shares under plan

BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, reported an open-market sale of 2,000 shares of common stock on February 26, 2026 at $66 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, reported an open-market sale of 2,000 shares of common stock on February 26, 2026 at $66 per share. The transaction was executed under a pre-arranged Rule 10b5-1 sales plan adopted on September 8, 2025. Following this sale, Apuli directly holds 121,945 BridgeBio shares.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider Apuli Maricel

Role Chief Accounting Officer

Sold 2,000 shs ($132K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$66.00	$132K

Holdings After Transaction: Common Stock — 121,945 shares (Direct)

Footnotes (1)

F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Pharma (BBIO) disclose in this Form 4 filing?

BridgeBio Pharma reported that Chief Accounting Officer Maricel Apuli sold 2,000 shares of common stock in an open-market transaction. The sale was made under a pre-arranged Rule 10b5-1 trading plan and left her with 121,945 directly held shares.

How many BridgeBio (BBIO) shares did Maricel Apuli sell and at what price?

Maricel Apuli sold 2,000 shares of BridgeBio common stock at $66 per share. This open-market sale was reported as a non-derivative transaction and executed under an established Rule 10b5-1 trading plan adopted earlier.

How many BridgeBio Pharma (BBIO) shares does the CAO own after this sale?

After the reported transaction, Chief Accounting Officer Maricel Apuli directly owns 121,945 shares of BridgeBio common stock. This figure reflects her holdings immediately following the 2,000-share open-market sale disclosed in the Form 4 filing.

Was the BridgeBio (BBIO) insider sale part of a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 sales plan adopted by Maricel Apuli on September 8, 2025. Such plans pre-schedule trades, helping separate personal trading from day-to-day corporate information.

Who is the insider involved in this BridgeBio Pharma (BBIO) Form 4?

The insider is Maricel Apuli, BridgeBio Pharma’s Chief Accounting Officer. She is an executive officer of the company and reported selling 2,000 shares of common stock while retaining 121,945 shares held directly after the transaction.

What type of transaction did BridgeBio (BBIO) report for its CAO?

BridgeBio reported an open-market sale of common stock by its Chief Accounting Officer. The Form 4 lists the transaction code as “S,” describing it as a sale in an open market or private transaction under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/27/2026 - 04:11 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		S⁽¹⁾		2,000	D	$66	121,945	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

Remarks:

	/s/ Maricel Apuli	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR